SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-259636
Filing Date
2022-10-07
Accepted
2022-10-07 16:30:56
Documents
12
Period of Report
2022-10-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K d407930d8k.htm   iXBRL 8-K 25402
  Complete submission text file 0001193125-22-259636.txt   146637

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pyxs-20221006.xsd EX-101.SCH 2864
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE pyxs-20221006_lab.xml EX-101.LAB 17980
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pyxs-20221006_pre.xml EX-101.PRE 11264
6 EXTRACTED XBRL INSTANCE DOCUMENT d407930d8k_htm.xml XML 3346
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

IRS No.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 221301088
SIC: 2834 Pharmaceutical Preparations